Skip to content
My WebMD Sign In, Sign Up

Cancer Health Center

Font Size
A
A
A

FDA: New Warning for Procrit, Epogen, Aranesp

Heart Attack, Stroke Risks Prompt Treatment Change for Chronic Kidney Disease Patients
By
WebMD Health News
Reviewed by Laura J. Martin, MD

June 24, 2011 -- New data show that the way Procrit, Epogen, and Aranesp are used in patients with chronic kidney disease (CKD) may put them at risk of heart attack, stroke, and death, the FDA today warned.

More than 20 million Americans age 20 and older have CKD. All CKD patients taking these drugs should contact their doctors. Those taking the drugs for other conditions should be aware of the risk.

The drugs, all made by Amgen, are known as erythropoiesis-stimulating agents or ESAs. They signal the bone marrow to make more red blood cells and reduce anemia due to CKD or cancer chemotherapy.

Patients with CKD lose some of their ability to make new red blood cells and sometimes need blood transfusions. ESAs reduce the need for these transfusions.

Doctors test patients' hemoglobin levels to adjust ESA dosing. Currently, they have shot for a goal of 10 to 12 g/dL hemoglobin in patients with CKD.

But new evidence shows that patients who achieve this goal may have a significantly increased risk of heart attack, heart failure, stroke, and death.

Beginning immediately, the FDA says doctors and patients should abandon the concept of a target hemoglobin goal. Instead they should use only the smallest ESA dose needed to reduce transfusion frequency -- and should frequently test patients' blood to make sure hemoglobin levels don't get too high.

The advice is different for CKD patients on dialysis and for CKD patients not on dialysis.

For CKD patients on dialysis:

  • Begin ESA treatment when the hemoglobin level is less than 10 g/dL.
  • If the hemoglobin level approaches or reaches 11 g/dL, reduce the ESA dose or suspend treatment.

For CKD patients not on dialysis:

  • Consider ESA treatment only when the hemoglobin level is less than 10 g/dL, and the rate of hemoglobin level decline suggests need for a blood transfusion is likely, and a goal of treatment is to reduce the risk of immunization against non-self factors in transfused blood and/or reducing transfusion risks.
  • If the hemoglobin level goes over 10 g/dL, reduce the ESA dose or suspend treatment.

"We now recommend that doctors and patients should weigh the possible benefits of ESAs to decrease the need for red-blood-cell transfusion against increased risk of serious cardiovascular events," Robert C. Kane, MD, FDA acting deputy director for safety of hematology products, said at a news teleconference. "For each patient, doctors should individualize dosing and use only the dose sufficient to reduce the need for transfusions."

Today on WebMD

Building a Support System
Blog
cancer fighting foods
SLIDESHOW
 
precancerous lesions slideshow
SLIDESHOW
quit smoking tips
SLIDESHOW
 
Jennifer Goodman Linn self-portrait
Blog
what is your cancer risk
HEALTH CHECK
 
colorectal cancer treatment advances
Video
breast cancer overview slideshow
SLIDESHOW
 
prostate cancer overview
SLIDESHOW
lung cancer overview slideshow
SLIDESHOW
 
ovarian cancer overview slideshow
SLIDESHOW
Actor Michael Douglas
Article